OPK - Opko Health Inc Summary, Stock Quote and News

1.590 -0.05 (-3.05%)

After Hours 1.59 (%)

Data as of Dec 05, 2019

Prev. Close 1.64
Price Open 1.67
Volume 4,692,609
Day's Range 1.59 - 1.68
52 Wk Range 1.33 - 3.935
50 Day Moving Avg. 1.76
PE Ratio 0
Shares Outstanding 665.60M
Market Cap 1.06B

Trade OPK stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
11/25/19	Piper Jaffray	Initiates Coverage On	Overweight	2.5
3/02/18	JP Morgan	Downgrades	NeutralUnderweight
9/14/17	JP Morgan	Downgrades	OverweightNeutral	7.0

17 Healthcare Stocks Moving In Thursday's Pre-Market Session Lisa LevinThu, 05 Dec 2019 07:55:33 -0500
Benzinga's Top Upgrades, Downgrades For November 25, 2019 Lisa LevinMon, 25 Nov 2019 09:34:34 -0500
UPDATE: Piper Jaffray On OPKO Health Is 'Confident in Somatrogon Approval'; Firm Projects Co's 'U.S. net Rayaldee sales to grow from $27.4 million this year to $40 million in 2020 and $52.5 million in 2021'; Notes 'BioReference and GeneDx Stabilizing' Benzinga_NewsdeskMon, 25 Nov 2019 09:09:39 -0500
UPDATE: Piper Jaffray Initiates OPKO Health With Overweight, $2.50 Target Notes 'Partner Pfizer recently reported positive Phase III data on once-weekly somatrogon in pediatric Growth Hormone Deficiency'; Pfizer Anticipates Filing 'BLA 2H:20' Benzinga_NewsdeskMon, 25 Nov 2019 09:09:28 -0500
OPKO Health shares are trading higher after Piper Jaffray initiated coverage on the stock with an Overweight rating and a $2.5 price target. Benzinga NewsdeskMon, 25 Nov 2019 08:30:24 -0500
Piper Jaffray Initiates Coverage On OPKO Health with Overweight Rating, Announces $2.5 Price Target Benzinga_NewsdeskMon, 25 Nov 2019 06:36:06 -0500
OPKO Health Reports Novitas Solutions Issued Final Local Coverage Determination For Medicare Payments For 4Kscore Test Benzinga NewsdeskFri, 15 Nov 2019 08:01:28 -0500
17 Healthcare Stocks Moving In Wednesday's Pre-Market Session Lisa LevinWed, 06 Nov 2019 07:52:37 -0500
Opko Health Q3 EPS $(0.11) Misses $(0.09) Estimate, Sales $228.8M Beat $225.4M Estimate luke@benzinga.comTue, 05 Nov 2019 16:35:56 -0500
OPKO Health shares are trading higher as a potential rebound after the stock fell roughly 25% last Friday following the company reporting a $100 million offering. Benzinga NewsdeskMon, 28 Oct 2019 14:24:49 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

OPKO Health to Participate in the 31st Annual Piper Jaffray Healthcare Conference Globe NewswireNov 26, 2019
Novitas Issues Final Local Coverage Determination for the 4Kscore® Test Globe NewswireNov 15, 2019
OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results Globe NewswireNov 05, 2019
BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders Globe NewswireNov 04, 2019
OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019 Globe NewswireNov 01, 2019
OPKO Health, Inc. Announces Pricing of its Offering of Common Stock Globe NewswireOct 24, 2019
OPKO Health, Inc. Announces Proposed Offering of Common Stock Globe NewswireOct 22, 2019
OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency Globe NewswireOct 21, 2019
OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency WebWireOct 21, 2019
OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement Business WireSep 04, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Why Is OPKO Health (OPK) Up 10.8% Since Last Earnings Report? Zacks6 hours ago
ViacomCBS, Amazon's AWS Event And Conference Blitz (Stocks To Watch Podcast) Seeking Alpha4 days ago
Stocks To Watch: ViacomCBS, Amazon's AWS Event And Conference Blitz Seeking Alpha5 days ago
Novitas Issues Final Local Coverage Determination for the 4Kscore® Test GuruFocusNov 15, 2019
Daily Insider Ratings Round Up 11/7/19 Seeking AlphaNov 11, 2019
Weekly CEO Buys Highlight GuruFocusNov 11, 2019
Insiders Roundup: Crocs, OPKO Health GuruFocusNov 08, 2019
OPKO Health, Inc. (OPK) CEO Dr. Phillip Frost on Q3 2019 Results - Earnings Call Transcript Seeking AlphaNov 05, 2019
OPKO Health (OPK) Reports Q3 Loss, Tops Revenue Estimates ZacksNov 05, 2019
Opko Q3 top line down 8% Seeking AlphaNov 05, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2019	EST	Actual	Surprise
EPS:	-0.090	-0.090	0.0000
Rev:	225.40M	228.80M	3.40M

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-02-26
Rev:	Expected 2020-02-26

Company Profile

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Opko Health Inc OPK:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Opko Health Inc OPK:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners